Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgery

HPB (Oxford). 2022 Feb;24(2):244-254. doi: 10.1016/j.hpb.2021.06.421. Epub 2021 Jul 8.

Abstract

Background: Loco-regional treatments have improved the survival of patients with early hepatocellular carcinoma (HCC), but tumor relapse is a frequent event and survival rates remain low. Moreover, conflicting evidences address early HCC patients to surgery or radiofrequency ablation (RFA), with the clinical need to find predictive non-invasive biomarkers able to guide treatment choice and define patients survival.

Methods: Two independent case series of treatment-naïve HCC patients treated with local RFA, and a cohort of 30 HCC patients treated with liver surgery were enrolled. On the basis of literature evidence, we customized a panel of 21 miRNAs correlated with relapse and prognosis after local curative treatment of HCC.

Results: Expression levels of let-7c predict tumor relapse after RFA; we also investigated the same panel in a small cohort of HCC patients undergoing surgery, finding no statistically significance in predicting tumor relapse or survival. Moreover, interaction test indicated that let-7c expression levels are predictive for identifying a subset of patients that should be addressed to surgery.

Conclusion: Results from this study could predict prognosis of early HCC patients, helping to address early HCC patients to surgery or RFA treatment.

MeSH terms

  • Carcinoma, Hepatocellular* / genetics
  • Carcinoma, Hepatocellular* / surgery
  • Catheter Ablation* / adverse effects
  • Catheter Ablation* / methods
  • Circulating MicroRNA* / genetics
  • Humans
  • Liver Neoplasms* / genetics
  • Liver Neoplasms* / surgery
  • MicroRNAs* / genetics
  • Neoplasm Recurrence, Local / pathology
  • Radiofrequency Ablation* / adverse effects
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Circulating MicroRNA
  • MicroRNAs